Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant

Journal of Infectious Diseases

Volumn 207, Issue 7, 2013, Pages 1047-1057

  Hsu, Hong Yuan ^a,b   Chang, Mei Hwei ^a   Ni, Yen Hsuan ^a   Jeng, Yung Ming ^a,b   Chiang, Cheng Lun ^a,b   Chen, Huey Ling ^a,b   Wu, Jia Feng ^a   Chen, Pei Jer ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

children; hepatitis B virus; immunization; long term follow up; natural history; surface gene mutant

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL FEATURE; CODON; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOPROPHYLAXIS; INCIDENCE; INFANT; LIVER CELL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; TREATMENT DURATION; TREATMENT FAILURE; VIRUS DETECTION; VIRUS LOAD;

EID: 84983722955     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis943     Document Type: Article

References (33)

1. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-9. (Pubitemid 20264145)
2. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345:1406-7.
3. Carman WF, Van Deursen FJ, Mimms LT, et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology 1997; 26:1658-66. (Pubitemid 27520038)
4. Waters JA, Kennedy M, Voet P, et al. Loss of common 'a' determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90:2543-7. (Pubitemid 23010076)
5. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B vaccine variants in Singapore. Vaccine 1995; 13:699-702.
6. Nainan OV, Khristova M, Byun K, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002; 68:319-27.
7. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30:1312-7.
8. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53:1499-503.
9. Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents fully covered by universal infant immunization. J Infect Dis 2010; 201:1192-200.
10. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 1997; 175:511-23. (Pubitemid 27086153)
11. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786-91.
12. Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen (-) liver disease. Antivir Ther 2001; 52:117-23. (Pubitemid 32973686)
13. Oon CJ, Tan KL, Harrison T. Natural history of hepatitis B surface antigen mutants in children. Lancet 1996; 348:1524. (Pubitemid 26400272)
14. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25 year universal vaccination program. J Hepatol 2012; 57:730-5.
15. Yeh SH, Tsai CY, Kao JH, et al. Combined real time PCR quantification and signature single nucleotide polymorphism genotyping of hepatitis B virus in one-tube reaction. J Hepatol 2004; 41:659-66.
16. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
17. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 1981; 78:3824-8. (Pubitemid 11060471)
18. Wu L, Yuan ZH, Liu F, Waters JA, Wen YM. Comparing the immunogenicity of hepatitis virus S gene variants by DNA immunization. Viral Immunol 2001; 14:359-67. (Pubitemid 34309064)
19. Kalinina T, Iwanski A, Will H, Streneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003; 38:1274-81. (Pubitemid 37314837)
20. Huang CH, Yuan Q, Chen PJ, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol 2012; 57:720-9.
21. Gilles PN, Guerrete DL, Ulevitch RJ, Schreiber RD, Chisari FV. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 1992; 16:655-63.
22. Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mother to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992; 32:264-8.
23. Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 2001; 33:218-23. (Pubitemid 32016905)
24. Niu J, He S, Su C, et al. Variability of the S gene of hepatitis B virus in southeastern China. Arch Virol 2010; 155:1951-7.
25. Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009; 49:1859-67.
26. Chang MH, Hsu HY, Hsu HC, et al. The significance of spontaneous hepatitis B antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before three years of age. Hepatology 1995; 22:1387-92.
27. Oon CJ, Chen WN, Zhao Y, Teng SW, Leong AL. Detection of hepatitis B surface antigen mutants and their integration in human hepatocellular carcinoma. Cancer Lett 1999; 136:95-9. (Pubitemid 29145219)
28. Chang MH, Chen TH, Hsu HM, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005; 11:7953-7. (Pubitemid 41611643)
29. Thakur V, Kazim SN, Guptan R, et al. Transmission of G145R mutant of HBV to an unrelated contact. J Med Virol 2005; 76:40-46. (Pubitemid 40446453)
30. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28:730-736.
31. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high edemicity region. J Viral Hepat 2011; 18:369-375.
32. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16:94-103.
33. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55:1215-1221.